Genocea Biosciences Inc. (GNCA) 8.90 $GNCA
Genocea Named in Top Places to Work List by The Boston Globe
Business Wire - Thu Nov 13, 10:52AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston's Top Places to Work by The Boston Globe.
GNCA: 8.90 (-0.04)
Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference
Business Wire - Wed Nov 12, 7:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 19, 2014 at 10:20 a.m. EST in New York, NY.
GNCA: 8.90 (-0.04)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 35.22 (-0.75), CMRX: 32.24 (-0.68), CVM: 0.65 (+0.04), ADMP: 4.09 (+0.15), GNCA: 8.90 (-0.04)
Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:49AM CST
GNCA: 8.90 (-0.04)
Genocea Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:26AM CST
GNCA: 8.90 (-0.04)
Genocea Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the third quarter ended September 30, 2014.
GNCA: 8.90 (-0.04)
Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes
Business Wire - Wed Nov 05, 11:01AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of antigens that may be a biomarker of disease. The findings, generated using Genocea's proprietary ATLAS(TM) antigen discovery platform, revealed that malaria leaves a lasting imprint on the immune system. Genocea researchers found evidence that this T cell immunological memory can be detected many years after the previous clinical episode of malaria. The study was presented at the 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene in New Orleans, LA.
GNCA: 8.90 (-0.04)
Genocea to Announce Third Quarter 2014 Financial Results on November 6, 2014
Business Wire - Thu Oct 30, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on November 6, 2014 at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 8.90 (-0.04)
Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 46.88 (-1.40), NVAX: 5.28 (+0.09), AMPE: 3.34 (-0.04), GNCA: 8.90 (-0.04)
Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek
Business Wire - Wed Oct 08, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the presentation of final data from the Phase 1/2a study of GEN-003, the company's immunotherapy candidate for treatment of genital herpes. The oral presentation, titled "Therapeutic HSV-2 Vaccine (GEN-003) Results in Durable Reduction in Genital Lesions at 1 Year ", will be given on Saturday, Oct. 11 at IDWeek 2014(TM) in Philadelphia.
GNCA: 8.90 (-0.04)
Genocea wins USD1.2m grant for malaria vaccine discovery
M2 - Wed Sep 24, 6:11AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Tuesday that it has received a USD1.2m grant for the identification of protective T cell antigens for malaria vaccines.
GNCA: 8.90 (-0.04)
Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery
Business Wire - Tue Sep 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.
GNCA: 8.90 (-0.04)
Genocea to Present at the 21st Annual NewsMakers in the Biotech Industry Conference
Business Wire - Fri Sep 19, 8:00AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the BioCentury 21st Annual NewsMakers in the Biotech Industry Conference. The presentation is scheduled for Friday, September 26, 2014 at 10:30 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York, NY.
GNCA: 8.90 (-0.04)
Virology Publishes Genocea HSV-2 Antigen Discovery Paper
Business Wire - Tue Sep 16, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS(TM) platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled "Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors," positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.
GNCA: 8.90 (-0.04)
Genocea reports launch of Phase 2a trial for universal pneumococcal vaccine candidate GEN-004
M2 - Fri Sep 12, 7:58AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) announced on Thursday that it has started its Phase 2a trial of its universal vaccine candidate against pneumococcus, GEN-004.
GNCA: 8.90 (-0.04)
Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Business Wire - Thu Sep 11, 1:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.
GNCA: 8.90 (-0.04)
Genocea Appoints Kenneth Bate to its Board of Directors
Business Wire - Thu Sep 11, 11:30AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee.
GNCA: 8.90 (-0.04)
Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC
Business Wire - Sat Sep 06, 3:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled "Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine," was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
GNCA: 8.90 (-0.04)
HSV-2 Vaccine in Development: CBCD Congratulates Genocea Biosciences (GNCA)
PRWeb - Sun Aug 17, 1:46AM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GNCA: 8.90 (-0.04)
Genocea Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
GNCA: 8.90 (-0.04)
Genocea Named in Top Places to Work List by The Boston Globe
Business Wire - Thu Nov 13, 10:52AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston's Top Places to Work by The Boston Globe.
GNCA: 8.90 (-0.04)
Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference
Business Wire - Wed Nov 12, 7:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 19, 2014 at 10:20 a.m. EST in New York, NY.
GNCA: 8.90 (-0.04)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 35.22 (-0.75), CMRX: 32.24 (-0.68), CVM: 0.65 (+0.04), ADMP: 4.09 (+0.15), GNCA: 8.90 (-0.04)
Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:49AM CST
GNCA: 8.90 (-0.04)
Genocea Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:26AM CST
GNCA: 8.90 (-0.04)
Genocea Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the third quarter ended September 30, 2014.
GNCA: 8.90 (-0.04)
Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes
Business Wire - Wed Nov 05, 11:01AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of antigens that may be a biomarker of disease. The findings, generated using Genocea's proprietary ATLAS(TM) antigen discovery platform, revealed that malaria leaves a lasting imprint on the immune system. Genocea researchers found evidence that this T cell immunological memory can be detected many years after the previous clinical episode of malaria. The study was presented at the 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene in New Orleans, LA.
GNCA: 8.90 (-0.04)
Genocea to Announce Third Quarter 2014 Financial Results on November 6, 2014
Business Wire - Thu Oct 30, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on November 6, 2014 at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 8.90 (-0.04)
Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 46.88 (-1.40), NVAX: 5.28 (+0.09), AMPE: 3.34 (-0.04), GNCA: 8.90 (-0.04)
Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek
Business Wire - Wed Oct 08, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the presentation of final data from the Phase 1/2a study of GEN-003, the company's immunotherapy candidate for treatment of genital herpes. The oral presentation, titled "Therapeutic HSV-2 Vaccine (GEN-003) Results in Durable Reduction in Genital Lesions at 1 Year ", will be given on Saturday, Oct. 11 at IDWeek 2014(TM) in Philadelphia.
GNCA: 8.90 (-0.04)
Genocea wins USD1.2m grant for malaria vaccine discovery
M2 - Wed Sep 24, 6:11AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Tuesday that it has received a USD1.2m grant for the identification of protective T cell antigens for malaria vaccines.
GNCA: 8.90 (-0.04)
Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery
Business Wire - Tue Sep 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.
GNCA: 8.90 (-0.04)
Genocea to Present at the 21st Annual NewsMakers in the Biotech Industry Conference
Business Wire - Fri Sep 19, 8:00AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the BioCentury 21st Annual NewsMakers in the Biotech Industry Conference. The presentation is scheduled for Friday, September 26, 2014 at 10:30 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York, NY.
GNCA: 8.90 (-0.04)
Virology Publishes Genocea HSV-2 Antigen Discovery Paper
Business Wire - Tue Sep 16, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS(TM) platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled "Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors," positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.
GNCA: 8.90 (-0.04)
Genocea reports launch of Phase 2a trial for universal pneumococcal vaccine candidate GEN-004
M2 - Fri Sep 12, 7:58AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) announced on Thursday that it has started its Phase 2a trial of its universal vaccine candidate against pneumococcus, GEN-004.
GNCA: 8.90 (-0.04)
Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Business Wire - Thu Sep 11, 1:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.
GNCA: 8.90 (-0.04)
Genocea Appoints Kenneth Bate to its Board of Directors
Business Wire - Thu Sep 11, 11:30AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee.
GNCA: 8.90 (-0.04)
Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC
Business Wire - Sat Sep 06, 3:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled "Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine," was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
GNCA: 8.90 (-0.04)
HSV-2 Vaccine in Development: CBCD Congratulates Genocea Biosciences (GNCA)
PRWeb - Sun Aug 17, 1:46AM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GNCA: 8.90 (-0.04)
Genocea Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
GNCA: 8.90 (-0.04)
